TRADING BIO

[TREND1]

Author’s reply » <<<< with the hope that they will earn the next $25M milestone payment for achieving some unspecified (to us) metric. If they don't earn it, they could go to the ATM and sell some shares.>>>

However, if they by some miracle get a $25 million milestone if they follow the same protocol they will carry this milestone as a liability and not operating cash/income. As I've stated many times, the Sanofi deal was a one-way street with all the benefit accruing to Sanofi. There is a simple reason that MNKD doesn't report milestone payments as being a cash asset. Find one other small biotech firm that has gotten milestone payments and see where they place such payments--as for as I've been able to find only MNKD has such filed as a liability. The key is very simple--only MNKD has agreed to a partnership deal where the partner(SNY) is paying the expenses being incurred by the partner(MNKD). SNY is stupid and would ever agree to such without a claw back arrangement locked in for each and every penny they have given or loaned to MNKD. Looked at the very moment that MNKD's stock cratered from the $11.47 high price when the SNY deal was announced--the moment being when MNKD filed their SEC documents outlining the fleece job SNY applied to MNKD. Go back to that day---look at the chart and the stock falling off a cliff, now down to $3.00.